Legal Opinion
In re Regeneron Pharmaceuticals, Inc. Securities Litigation
District Court, S.D. New York
Decided September 18, 2026No. 1:25-cv-00145Unknown
1Opinion
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK 9/18/26 No. 1:25-cv-145 (MKV) In re Regeneron Pharmaceuticals, Inc. Securities Litigation. OPINION AND ORDER GRANTING MOTION TO DISMISS MARY KAY VYSKOCIL, United States District Judge: Lead Plaintiff in this putative securities class action contends that Defendant Regeneron Pharmaceuticals, Inc., and a number of its executives, engaged in two different securities frauds involving two versions of its retinal disease drug, “Eylea,” Regeneron’s signature drug, which has been on the market for years, and “Eylea HD,” a new, high-dose…
2Cases cited29 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Tellabs, Inc. v. Makor Issues & Rights, Ltd.Supreme Court of the United States · 2007
- Ernst & Ernst v. HochfelderSupreme Court of the United States · 1976
- ATSI Communications, Inc. v. Shaar Fund, Ltd.Court of Appeals for the Second Circuit · 2007
24 more not listed; retrieve them via the Exa API.